RAPID BREATH DETECTION OF LUNG CANCER

iSense医疗公司（IMC）用于检测呼吸中肺癌特征的传感器系统的灵敏度将得到增强和演示，一种新的呼吸收集装置将完成，克利夫兰诊所基金会（CCF）针对8000名肺癌患者和对照组的ELDDA研究的协议修改将完成。20世纪80年代，第一代无创、廉价、快速检测肺癌的方法已经在CCF进行了特异性和选择性检测。下一代传感器阵列，包括嵌入在纳米多孔溶胶-凝胶基质中的光学指示器，现在对一系列肺癌呼吸标志物的灵敏度提高了100倍，提高了已经被证明在肺癌检测中有效的乳房传感器技术的灵敏度。已批准的CCF方案将被改进，以评估在进行不确定的肺部CT和IMC呼吸测试后将肺癌诊断假阳性减少200%以上的具体声明。此外，由于肺癌的呼吸特征源于活跃的肿瘤代谢，该方案将适用于测试IMC呼吸休息代表化疗疗效快速和低成本评估的假设。

The sensitivity of iSense Medical Corp (IMC) sensor system for the detection of a lung cancer signature from breath will be enhanced and demonstrated, a new breath collection device completed and a modification of the Cleveland Clinic Foundation (CCF) protocol for the ELDDA study of 8000 lung cancer patients and controls will be completed. The first generation of this non-invasive, inexpensice and rapid assay for the presence of lunf cancer has already been tested at CCF wwith specificity and selectivity of detection in the 80s. The next generation of this sensor array,comprising optical indicators embedded in a nanoporous sol-gel matrix is now>100x more sensitive to a range of lung cancer breath markers, enhancing sensitivty for a breast sensor technology already proven effective in lung cancer detection. The approved CCF protocol will be refined to assess the specific claim that following an indeterminate lung CT witht he IMC breath test reduces lung cancer diagnosis false positives over 200%. Further, as lung cancer breath signature arises from active tumor metabolism, the protocol will be adapted to test the hypothesis that the IMC breath rest represents a rapid and low-cost assessment for the efficacy of chemotherapy.